Skip to main content

Table 3 Vaccine efficacy against IPD and pneumonia

From: Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting

 

IPD

Pneumococcal pneumonia

Age/risk group

Year 1

Year 5

Year 10

Year 15

Year 16+

Year 1

Year 5

Year 10

Year 15

Year 16+

PCV20

18–49 years

          

Low risk

82%

82%

63%

37%

0%

56%

56%

43%

23%

0%

At risk

78%

78%

61%

36%

0%

53%

53%

41%

24%

0%

High risk

65%

65%

50%

30%

0%

44%

44%

34%

20%

0%

50–64 years

          

Low risk

79%

79%

61%

36%

0%

51%

51%

40%

23%

0%

At risk

76%

76%

59%

35%

0%

49%

49%

38%

23%

0%

High risk

63%

63%

49%

29%

0%

41%

41%

32%

19%

0%

65 + years

          

Low risk

75%

75%

58%

34%

0%

45%

45%

35%

21%

0%

At risk

72%

72%

56%

33%

0%

43%

43%

33%

20%

0%

High risk

60%

60%

46%

27%

0%

36%

36%

28%

16%

0%

PPV23

18–49 years

          

Low risk

59%

45%

0%

0%

0%

-

-

-

-

-

At risk

30%

23%

0%

0%

0%

-

-

-

-

-

High risk

17%

13%

0%

0%

0%

-

-

-

-

-

50–64 years

          

Low risk

58%

44%

0%

0%

0%

-

-

-

-

-

At risk

29%

22%

0%

0%

0%

-

-

-

-

-

High risk

17%

13%

0%

0%

0%

-

-

-

-

-

65–74 years

          

Low risk

56%

42%

0%

0%

0%

-

-

-

-

-

At risk

28%

21%

0%

0%

0%

-

-

-

-

-

High risk

16%

12%

0%

0%

0%

-

-

-

-

-

75–84 years

          

Low risk

51%

39%

0%

0%

0%

-

-

-

-

-

At risk

25%

19%

0%

0%

0%

-

-

-

-

-

High risk

15%

11%

0%

0%

0%

-

-

-

-

-

85–99 years

          

Low risk

38%

29%

0%

0%

0%

-

-

-

-

-

At risk

19%

14%

0%

0%

0%

-

-

-

-

-

High risk

11%

8%

0%

0%

0%

-

-

-

-

-

  1. Note: The table shows the vaccine efficacy and waning of PPV23 and PCV20 against IPD and pneumonia between year 1 and 16 after vaccination. In the base case analysis, PPV23 was assumed not to have any efficacy against pneumonia. Confidence intervals are provided in parentheses. IPD: invasive pneumococcal diseases; PCV20: 20-valent pneumococcal conjugate vaccine; PPV23: 23-valent pneumococcal polysaccharide vaccine. Sources: [17, 19, 29]
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us